MELA Sciences announced that it has initiated a study to examine the real-world clinical impact of MelaFind on dermatologists' decision to biopsy pigmented skin lesions that are suspicious for melanoma. CEO Rose Crane commented, "This trial is significant as the data will be based on patient assessments by dermatologists using the MelaFind system. It will provide us with a measure of the real-world clinical impact of MelaFind on melanoma diagnosis, and we believe it will support our case for insurance reimbursement. We welcome Dr. Rigel's oversight as the principal investigator of this important study."